Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2019-09-03 Regulatory Filings
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It is a current report filed with the SEC to disclose material events or corporate changes. The content describes a correction to a previously reported collaboration and license agreement, including milestone payments and upfront payments. There are no financial statements or detailed financial performance data, nor is it a full annual or quarterly report. It is not a proxy, earnings release, or management discussion. The document is an amendment to a current report about a material definitive agreement, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit other more specific categories. The document length is under 5,000 characters and it is an amendment, not the original report itself, so it is not a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2019-09-03 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes a Collaboration Agreement and a Stock Purchase Agreement entered into by the company, including details about the agreements, financial terms, and related stock issuance. It also references a press release and states that full agreements will be attached to the upcoming 10-Q filing. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, audit report, or governance information. It is a regulatory announcement of material agreements and financing activity. Therefore, the best fitting category is Capital/Financing Update (CAP), as it includes a private placement of shares and collaboration financial terms. The document length and detail support this classification with high confidence.
2019-09-03 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically discusses an extension of a deadline related to a Loan and Security Agreement amendment, which pertains to financing activities. There are no financial statements or comprehensive financial data presented, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a report publication announcement or certification. The focus on loan agreement amendment and financial covenant milestone aligns with capital or financing updates. Therefore, the document is best classified as a Capital/Financing Update (CAP). The document length is 3193 characters, which is consistent with a typical 8-K filing for such an event.
2019-08-29 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 14, 2019. It announces that Cidara Therapeutics, Inc. will present at the 2019 Wedbush PacGrow Healthcare Conference and includes a slide presentation as an exhibit. The content is primarily an announcement of an investor presentation event and the attached presentation slides. The document length is 3091 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, announcements of presentations with attached slides fall under Investor Presentation (IP). Therefore, the filing type is Investor Presentation (IP).
2019-08-14 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q2 2019
2019-08-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2019, reporting financial results for the second quarter ended June 30, 2019. It includes a press release as an exhibit with the financial results. The document is relatively short (3904 characters) and primarily serves as a current report announcing the earnings release rather than containing the full financial statements or detailed analysis itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). The document explicitly states it is reporting financial results for the quarter and includes a press release with those results, fitting the definition of an Earnings Release.
2019-08-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.